Confinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux Mechanism

PLoS One. 2015 Aug 21;10(8):e0136231. doi: 10.1371/journal.pone.0136231. eCollection 2015.

Abstract

Tuberculosis (TB) is the world's deadliest curable disease, responsible for an estimated 1.5 million deaths annually. A considerable challenge in controlling this disease is the prolonged multidrug chemotherapy (6 to 9 months) required to overcome drug-tolerant mycobacteria that persist in human tissues, although the same drugs can sterilize genetically identical mycobacteria growing in axenic culture within days. An essential component of TB infection involves intracellular Mycobacterium tuberculosis bacteria that multiply within macrophages and are significantly more tolerant to antibiotics compared to extracellular mycobacteria. To investigate this aspect of human TB, we created a physical cell culture system that mimics confinement of replicating mycobacteria, such as in a macrophage during infection. Using this system, we uncovered an epigenetic drug-tolerance phenotype that appears when mycobacteria are cultured in space-confined bioreactors and disappears in larger volume growth contexts. Efflux mechanisms that are induced in space-confined growth environments contribute to this drug-tolerance phenotype. Therefore, macrophage-induced drug tolerance by mycobacteria may be an effect of confined growth among other macrophage-specific mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / metabolism
  • Antitubercular Agents / pharmacology*
  • Bacterial Load
  • Biological Transport
  • Cinnamates / metabolism
  • Cinnamates / pharmacology
  • Diffusion
  • Dimethylpolysiloxanes
  • Drug Tolerance / genetics*
  • Epigenesis, Genetic
  • Humans
  • Hygromycin B / analogs & derivatives
  • Hygromycin B / metabolism
  • Hygromycin B / pharmacology
  • Isoniazid / metabolism
  • Isoniazid / pharmacology
  • Lab-On-A-Chip Devices*
  • Macrophages / microbiology
  • Microdialysis
  • Models, Biological*
  • Mycobacterium smegmatis / drug effects*
  • Mycobacterium smegmatis / genetics
  • Mycobacterium smegmatis / growth & development
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / growth & development
  • Ofloxacin / metabolism
  • Ofloxacin / pharmacology
  • Phenotype
  • Rifampin / metabolism
  • Rifampin / pharmacology

Substances

  • Antitubercular Agents
  • Cinnamates
  • Dimethylpolysiloxanes
  • Hygromycin B
  • hygromycin A
  • baysilon
  • Ofloxacin
  • Isoniazid
  • Rifampin